Skip to content

Immunome IMNM Free cash flow yield

Free cash flow yield at other companies

Pfizer logo
PfizerPFE
7.8%+4.6pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-18.1%
Nuvation Bio logo
Nuvation BioNUVB
-9%-3.6pp
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-3%-1.4pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-3.8%-1.6pp
Summit Therapeutics logo
Summit TherapeuticsSMMT
-2.6%-20.9pp

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
Enterprise value$1.61B+470%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Calculated from Immunome’s reported figures.

Based on trailing twelve months.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's free cash flow yield?
Immunome (IMNM) reported free cash flow yield of -8.3% in Q1 2026.
How has Immunome's free cash flow yield changed year-over-year?
Immunome's free cash flow yield increased by 69.9% year-over-year, from -27.6% to -8.3%.
What is the long-term trend for Immunome's free cash flow yield?
Over 4 years (2020 to 2025), Immunome's free cash flow yield has grown at a -6.0% compound annual growth rate (CAGR), from -10.9% to -8.5%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.